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Abstract
Background: Practice effects (PEs) are improvements in performance after repeated
exposure to test materials, and typically viewed as a source of bias in repeated cognitive assessments. We aimed to determine whether characterizing PEs could also provide a useful marker of early cognitive decline.
Methods: We conducted a systematic review of the literature, searching PsycInfo
(Ebsco) and PubMed databases for articles studying PEs in aging and dementia populations. Articles published between 1920 and 2019 were included.
Result: We identified 259 articles, of which 27 studied PEs as markers of cognitive
performance. These studies consistently showed that smaller, less-robust PEs were
associated with current diagnostic status and/or future cognitive decline. In addition,
lower PEs were associated with Alzheimer’s disease risk factors and neurodegeneration biomarkers.
Conclusion: PEs provide a potentially useful marker of cognitive decline, and could
prove valuable as part of a cost-effective strategy to select individuals who are at-risk
for dementia for future interventions.
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BACKGROUND
HIGHLIGHTS

Practice effects (PEs) are expected improvements in cognitive per-

∙ We reviewed published research that studied practice

formance seen on repeated exposure to test material in the absence
of

intervention.1

effects (PEs) as markers of cognitive performance
∙ Lower PEs may associate with current cognitive status and

PEs, also referred to as retest or learning effects,

are typically viewed as a source of bias or error when analyzing data

predict future decline
∙ Lower PEs may associate with specific biological risk fac-

from repeated cognitive assessments,2,3 particularly in the study of
Alzheimer’s disease (AD) and other neurodegenerative disorders lead-

tors for Alzheimer’s disease

ing to dementia where cognitive decline is a key marker of clinical
change.4,5

PEs can hinder our understanding of the disease course of

AD and other neurodegenerative diseases, as well as improve the evaluation of interventions that aim to slow or halt cognitive decline.6 That
is, by masking cognitive decline due to an underlying neurodegenerative process or by inflating cognitive gain in the absence of treatment

RESEARCH IN CONTEXT

induced brain changes, PEs may lead to underestimating the sever-

1. Systematic review: The authors conducted a systematic

ity of disease progression or overestimating the efficacy of treatment

review of the literature, searching PsycInfo and PubMed

effects.7

databases for articles studying practice effects (PEs) on

The absence of PEs may also provide useful information in the con-

cognitive testing in aging and dementia populations. Of

text of AD and dementia. More specifically, one might expect attenu-

259 identified articles, 27 studied PEs as a clinically useful

ated PEs in disorders such as mild cognitive impairment (MCI) and AD,

marker of cognitive performance in older adults.

in which learning is compromised. This was, for example, supported by

2. Interpretation: We found accumulating evidence that

Duff et al.,8 who showed that lower PEs were predictive of cognitive

lower PEs may represent an early indicator of cogni-

decline 1 year later in individuals with MCI. Another study found that

tive decline, and that lower PEs associate with specific

cognitively healthy older adults who later progressed to AD demen-

Alzheimer’s disease (AD) biological risk factors. The com-

tia had substantially lower PEs on episodic memory tasks compared

bination of quantifying PEs and assessing AD biomarkers

to those who remained cognitively healthy.9 Together, these findings

may yield an optimal approach to estimate AD risk.

suggest that lower PEs may indicate a subtle cognitive impairment pre-

3. Future directions: Future research should focus on iden-

ceding overt reduction in cognitive performance, and may serve as an

tifying high-risk individuals from a combination of cogni-

early marker to differentiate neurodegeneration from healthy cogni-

tive and clinical features, AD biomarkers, and lower than

tive aging. This would be of particular relevance in pre-dementia dis-

expected PEs. This could yield a cost-effective strategy

ease stages such as MCI or subjective cognitive decline, when objective

to enrich samples in clinical trials and provide a valuable

cognitive decline is modest or not easily captured by traditional cogni-

cognitive marker for subtle pharmacological or treatment

tive assessments.10,11 Therefore, the aim of the current review was to

responses.

examine the role of PEs as a potential marker for cognitive decline in
the study of cognitive aging.
Previous summaries of the PE literature in aging populations have
largely focused on PEs as a source of bias. An example is the metaanalysis by Calamia et al., which examined the magnitude of PEs on

Although PEs have been investigated and addressed in many stud-

several widely-applied cognitive tests (both memory and non-memory

ies for over a century, we sought to consolidate and compare studies by

tests), and investigated the influence of age, test-retest interval, use of

conducting a literature review of published research relevant to aging

effects.12

Of interest,

and dementia. More specifically, we aimed to summarize research that

they found that clinical groups (ie, patients with neurological or psychi-

investigated whether the presence or absence, or magnitude of PEs

atric conditions) showed lower PE on average compared to cognitively

could (1) be an indicator of current diagnostic status (ie, cognitively

healthy adults. The authors concluded that PEs should be accounted

normal, MCI, or dementia); (2) predict future cognitive decline or pro-

for in cognitively healthy populations to accurately assess group-level

gression to dementia; and/or (3) relate to AD risk factors or biomarkers

changes. Moreover, this finding also suggests that lower PEs in patient

of neurodegeneration.

alternate forms, and clinical diagnosis on those

groups may reflect a cognitive (ie, learning) deficit, which could serve
as a clinical marker of interest. The potential value of PEs as an indi-

2

METHODS

cator or marker of dementia risk is further supported by other studies, which suggest that PEs could serve as a proxy of specific fluid

2.1

Search strategy

or imaging AD biomarkers,13 or could be used in combination with
those biomarkers to identify individuals at greatest risk for clinical

The authors obtained published empirical studies through a systematic

progression.14

search of the PsycInfo (Ebsco) and PubMed databases. Based on
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consultation with research medical librarians (DKNL and JR), our
search strategy used the following key search terms: practice effects,

TA B L E 1 Theme definitions and related hypotheses of articles
from Category C

learning effects, retest effects, repeat testing, serial testing, serial

Theme 1

Practice Effect Variability Defines Cases
Hypothesis: Lower practice effects in mild cognitive
impairment and Alzheimer’s disease/dementia could
serve as additional evidence for presence of prodromal
or clinical dementia conditions.

Theme 2

Practice Effect Variability Predicts Outcomes
Hypothesis: Lower practice effects may be an important
early indicator of longitudinal outcomes such as
cognitive decline, change in cognitive test scores, change
in diagnostic status, or incidence of MCI or dementia.

Theme 3

Practice Effects Associate With AD Risk Factors
Hypothesis: Lower practice effects are associated with
various Alzheimer’s disease risk factors/biomarkers.

assessment, longitudinal testing, neuropsychological testing, cognitive
change, reliability, and early detection. A full text and abstract were
required for inclusion; there were no restrictions for date of publication or language. The authors also manually examined the references
of relevant studies to identify additional articles. Searches were
conducted on December 14, 2017, and on April 18, 2019, December
2, 2019, and January 31, 2020, to include published manuscripts of
interest.

2.2

Screening and review process

We selected articles using the following steps:
available), study design (ie, cross-sectional, longitudinal, or mixed),
1. Identification. Two authors (EG and LAR) reviewed titles and

method of quantifying PEs, research findings, and conclusions. With

abstracts to identify peer-reviewed full-text articles focusing on

regard to study design, for the purpose of the current article, the term

PEs in aging samples or important analytic/statistical issues about

“cross-sectional” was applied to studies for which the PEs (ie, second

modeling PEs, which were selected for subsequent evaluation.

testing to define a retest effect) were measured concurrently with

2. Initial screening. Research team members (NSF, PKC, LAR, MLL, RJJ,

the outcome of interest (eg, current diagnostic status); by contrast,

SAMS, and RNJ) evaluated full texts of articles identified in Step

the term “longitudinal” was applied to studies in which retesting to

1. One investigator reviewed each article and introduced it to the

identify PEs preceded the outcome being measured (eg, progression

group for discussion to classify the article in the subsequent step.

to dementia, change in cognitive test scores). All data were extracted

3. Eligibility. Based on the full-text evaluations, articles were catego-

by one author (EG) and verified by a second author (LAR). Descriptive

rized as (A) PEs as a nuisance variable and possible solutions; (B)

analyses on study population, age, retest interval, cognitive domains,

measuring and understanding the construct of PEs (eg, underlying

cognitive task, and methods of quantifying PEs were performed by

mechanisms, moderators); and/or (C) PEs as a potential measure of

synthesizing the data across all of the relevant articles and presented

cognitive change. Categories were not mutually exclusive, meaning

in one overview table. Subsequently, data were summarized by theme

that articles could be assigned to multiple categories.

to investigate whether PEs were associated with (1) current diagnostic

4. Inclusion in the current study. The goal of the current article was
to determine whether PEs could provide clinically useful informa-

status; (2) future cognitive decline or change in diagnostic status; and
(3) AD risk factors.

tion in the context of dementia or dementia risk, and we therefore further evaluated articles within Category C (ie, reported practice effects as a valuable measure of cognitive change). Each Cate-

3

RESULTS

gory C article was reviewed by two independent investigators (from
among authors NSF, PKC, LAR, MLL, RJJ, SAMS, RNJ, and EG) and

Figure 1 shows the results from the screening and review processes.

assigned to at least one theme: (1) PE variability defines cases; (2)

The search identified 259 articles published between October 1920

PE variability predicts outcomes; and (3) PEs associate with AD risk

and December 2019. We determined that 107 of these investigated

factors (Table 1). Articles could be assigned both primary and sec-

either PEs on cognitive tests in aging samples or methods on modeling

ondary themes. The authors also rated each article’s methodologi-

PEs, and underwent full-text evaluation by research team members. Of

cal rigor as low, medium, or high. If an article was identified as hav-

those, 27 met eligibility for Category C and were included in the cur-

ing more than one theme, it was assigned a secondary theme. If two

rent study. We assigned six of the 27 articles to primary Theme 1 (22%),

investigators disagreed on the theme(s) or quality of an article, it

10 to primary Theme 2 (37%), and 11 to primary Theme 3 (41%). We

was reviewed by a third investigator.

assigned secondary themes for five of the articles (three to Theme 3
and two to Theme 1).
Table 2 displays the key study characteristics of the 27 articles con-

2.3

Data extraction

sidered in this article. Studies in these reports included from n = 25 to
n = 1390 participants, with mean ages ranging from 53.4 to 83 years,

The following data were extracted from each included article: study

with an overall average of 73.6 years. Studies evaluated several dif-

population (ie, normal cognition, MCI, and/or dementia), mean age,

ferent diagnostic groups, retest intervals, cognitive domains and tasks,

retest interval, cognitive domains, cognitive task, biomarkers (if

and used different methods to calculate PEs (Table 2). Most studies

1 wk

Same day

Every 18 mos
(> 14 yrs)

1 wk

1 wk and 1
year

2 wks, 3 mos.,
& 6 mos

1 wk

Same day

1 wk

1 wk

Darby et al.17

Dodge et al.18

Duff et al.19

Duff et al.20

Duff et al.21

Duff et al.22

Duff et al.23

Duff, et al.24

Duff et al.25

1-4 days

Cooper et al.16

Cooper et al.

15

Retest
interval

MCI vs. Normal
Cognition

MCI vs. Normal
Cognition

MCI

MCI vs. Normal
Cognition

MCI

MCI vs. Normal
Cognition

MCI vs. Normal
Cognition

Normal Cognition

MCI vs. Normal
Cognition

AD vs. MCI vs.
Normal
Cognition

AD vs. Normal
Cognition

Baseline groups

Memory (verbal, visual);
Attention & psychomotor
speed; Visual scanning/
processing speed;
Premorbid intellect

Visual memory

Global cognitive function

Memory; Visuospatial
constructive skills;
Language; Attention

Visual learning; Global
cognitive function;
Psycho-motor speed;
Memory; Language

Memory; Non-memory

Visual processing speed;
Psychomotor speed;
Memory (verbal, visual)

Learning; Memory;
Language; Psycho-motor
speed; Executive function

Memory (episodic, working);
Attention; Psycho-motor
speed

Memory (episodic)

Memory (episodic)

Cognitive domains

HVLT-R; BVMT-R;
SDMT; TMT-A & B;
WRAT-4

BVMT-R

HVLT-R; MMSE

TMT-A & B; SDMT;
BVMT-R; COWAT;
HVLT-R; Animal
fluency

BVMT-R; MMSE;
TMT-A & B; HVLT-R;
WAIS-R; BNT;
COWAT; SDMT

BVMT-R; HVLT-R;
COWAT; Animal
fluency; TMT-A & B;
SDMT

HVLT-R; BVMT-R;
SDMT; TMT-A & B

MMSE; TMT-A & B;
CERAD; BNT

Non-standardized
measures

AMT

AMT

Cognitive tasks

Amyloid uptake

Amyloid uptake

N/A

N/A

N/A

N/A

Hippocampal volume

N/A

N/A

N/A

N/A

Biomarkers

Longitudinal

Longitudinal

Longitudinal

Longitudinal

Longitudinal

Longitudinal

Longitudinal

Mixed

Longitudinal

Longitudinal

Longitudinal

Correlation/
regression

Correlation/
regression

Change score;
Correlation/
regression

Change score

Correlation/
regression

Change score

Z-score difference

T-test of difference
score

Change score

Change score

Change score

Cross- sectional/
How PEs calcuLongitudinal/Mixed lated/quantified

Overview of the n = 27 included articles studying practice effects as a marker of cognitive performance in aging and dementia populations

Research article
and reference
number

TA B L E 2

(Continues)

77.5 years / n = 27

74.6 years / n = 25

73.3 years / n = 61

∼80 years / n = 121

72.4 years / 3
different samples
(n = 80, n = 33,
n = 170)

78.7 years / n = 127

77.5 years / n = 25

∼72 years / n = 1,230

n/a / n = 60

∼ 69 years / n = 69

∼70 years/ n = 123

Mean age/ and total n
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3 yrs

4 yrs x1 then 2 Normal cognition
yrs x10
(AD family
history vs.
none)

15 mos (x3)

Ihara et al.29

Jonaitis et al.30

Machulda et al.31

Normal Cognition

MCI and Normal
Cognition

Normal Cognition

Every 6 mos
(x3)

Amnestic MCI

Howieson et al.28

1 wk

Hanyu et al.27

Normal Cognition

Normal Cognition

Yearly (x6)

Galvin et al.26

MCI vs. Normal
Cognition

MCI vs. Normal
Cognition

Baseline groups

Hassenstab et al.9 ∼2 mos

1 wk

∼1 wk

Duff et al.8

Duff et al.

13

Retest
interval

(Continued)

Research article
and reference
number

TA B L E 2

Cognitive tasks

WMS-R; Category
fluency; MMSE

WMS; BVRT; Word
fluency; WAIS;
TMT-A; BNT

WRAT-3; 3MS; RBANS;
BVMT-R; HVLT-R;
COWAT; TMT-A & B;
SDMT

Memory; Language;
Visuospatial function;
Attention/ Executive
function

Verbal learning & recall;
Executive function; Visual
learning & memory

Memory (episodic); Global
cognition; Executive
function; Visuospatial
function

Memory; Language;
Visuospatial constructive
skills

AVLT; WMS-R; BNT;
Category fluency;
WAIS-R; TMT-B

RAVLT; BVMt; WMS

MMSE; ADAS; WMS-R;
WAIS-R; Category
fluency; TMT; BNT;
CDT; CCT

WMS; Category
fluency; WAIS-R

Memory (episodic, semantic); FCSRT; WMS; WMS-R;
WAIS; BNT; Animal
Executive function;
Naming; TMT-A & B
Visuospatial function;
Global cognitive function

Logical memory; Language;
Global cognitive function

Memory (primary, working,
episodic, verbal);
Visuospatial constructive
skills; Language

Memory (objective,
immediate, delayed);
Premorbid intellect;
Executive function;
Attention; Language;
Visuospatial constructive
skills

HVLT-R; BVMT-R;
Learning & memory;
TMT-A & B; SDMT;
Attention & processing
TMT-A; COWAT;
speed; Executive function;
WRAT-4; MMSE
Premorbid intellect; Global
cognitive function

Cognitive domains

Longitudinal

Longitudinal

Longitudinal

Longitudinal

Longitudinal

Mixed

Longitudinal

Hippocampal volume,
brain
hypometabolism;
Amyloid status

Longitudinal

Z-score difference

Change score

Correlation/
regression

Correlation/
regression

Correlation/
regression

T-test difference

Correlation/
regression

Change score

Correlation/
regression

Cross- sectional/
How PEs calcuLongitudinal/Mixed lated/quantified

AD family history of
Longitudinal
AD; APOE genotype

Amyloid uptake APOE

N/A

APOE genotype

N/A

Amyloid deposition,
Braak and Braak
stage,
Neurofibrillary
scores, Lewy bodies,
cortical infarcts &
hemorrhages

N/A

Brain
hypo-metabolism

Biomarkers

(Continues)

∼75 years / n = 190

∼54 years / n = 594

∼68 years / n = 84

83 years / n = 156

74.5 years / n = 263

∼ 76 years / n = 39

80.7 years / n = 80

∼80.6 years / n = 108

74.6 years / n = 25

Mean age/ and total n
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6 wks

2-3 yrs

17 mos

Yearly (x5)

2.4 yrs

1 wk (8 total)

SanchezBenavides
et al.33

Schrijnemaekers
et al.34

Suchy et al.35

Wilson et al.36

Zehnder et al.37

Most Frequent

Normal Cognition
(23 total)

AD vs. Normal
Cognition

Normal Cognition
group

MCI

Normal Cognition

Normal Cognition
(Family history
of AD vs. APOE
genotype)

MCI vs. Normal
Cognition

Normal Cognition

Baseline groups

DRS-2

HVLT; MMSE

Visuospatial/ constructive
ability (10 total)

Global cognitive function

TMT (14 total)

CERAD-NAB (German
version: included the
- BNT, MMSE, Animal
fluency, Word list
I-III, Figures-copy,
Word-list delayed
recall, Word list
recognition,
Figures-delayed
recall)CDT

Memory (episodic, semantic, WMS; Category
working); Perceptual
fluency; BNT; Word
speed; Visuo-spatial ability
Reading Test; SDMT;
Judgment Line
Orientation;
Standard Progressive
Matrices

General cognition status;
Attention;
Visual-constructive ability

Memory
Global cognitive function

Longitudinal

Longitudinal

Longitudinal

Mixed

Higher amyloid uptake Longitudinal (24
on amyloid PET
total)
scans (4 found an
effect and 2 did not)

N/A

Tangles, beta-amyloid,
and hippocampal
volume

N/A

N/A

APOE genotype
Longitudinal
Family history of AD

WAIS-IV

Memory (short-term,
working, visual);
Processing speed; Visual
perception; Coordination;
Attention

Longitudinal

Longitudinal

Correlation/
regression (11
total)

Z-score difference

Change point
modelschange
score

Correlation/
regression

Correlation/
regression

T-test difference

Z-score difference

Z-score difference

Cross- sectional/
How PEs calcuLongitudinal/Mixed lated/quantified

APOE genotype

APOE genotype

Biomarkers

AVLT

AVLT; WMS-R; BNT;
Category fluency;
WAIS-R; TMT-B

Cognitive tasks

Memory

Memory; Language;
Visuospatial function;
Attention/ Executive
function

Cognitive domains

Total average (73.57
years / n = 272)

∼71.25 / n = 469

78.7 years / n = 567

∼70 years / n = 75

∼76 years / n = 101

53.43 years / n = 400

∼74 years / n = 1,210

78.1 years / n = 1,390

Mean age/ and total n

Abbreviations: 3MS, modified mini-mental state examination; AD, Alzheimer’s disease; ADAS, Alzheimer’s disease assessment scale; AVLT, auditory verbal learning test; BNT, Boston naming test; BVMT(-R), brief
visuospatial memory test (revised); CCT = clock copying test; CDT = clock drawing test; CERAD, consortium to establish a registry for Alzheimer’s disease; COWAT, controlled oral word association test; DRS,
dementia rating scale; FCSRT, free and cued selective reminding test; HVLT, Hopkins verbal learning test; MCI, mild cognitive impairment; MMSE, mini-mental state examination; RBANS, repeatable battery for the
assessment of neuropsychological status; SDMT, symbol digit modalities test; TMT, trail making test; WAIS(-R), Wechsler adult intelligence scale (revised); WMS(-R), Wechsler memory scale (revised); WRAT-3,
wide range achievement test.

6-72 mos

15 mos
(x2-x5)

Oltra-Cucarella
et al.14

Machulda et al.

32

Retest
interval

(Continued)

Research article
and reference
number

TA B L E 2
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FIGURE 1
process

Overview of the screening and review

(n = 23, 85%) recruited cognitively healthy older adults, whereas 15

cognitively healthy elderly showed significantly greater PEs on aver-

studies (56%) recruited participants with MCI, and only 3 studies (11%)

age than individuals with MCI or dementia on both memory and

recruited individuals with AD dementia. Retest intervals ranged from

non-memory cognitive tasks.15,16,23,37 One study found that lower

same day to 4 years, where seven studies (26%) included additional

PEs in individuals with MCI could be detected after multiple repeated

multiple retest assessments (Figure 2). Ten articles included visuospa-

assessments on the same day.17 Conversely, Duff et al. reported that

tial functioning or construction, nine articles included language, nine

some individuals with amnestic MCI had PEs in delayed recall similar

articles included attention, eight articles included executive function-

to those found in cognitively healthy older adults. However, when the

ing, seven articles included episodic memory, four articles included psy-

amnestic MCI group was split into those who remained stable (“MCI-

chosocial speed, and four articles included working memory. To calcu-

stable,” classified as MCI both at baseline and 1 week follow-up) and

late PEs, 12 (44%) of the studies used correlation or regression analy-

those who improved and subsequently appeared intact (“MCI-normal,”

ses, 8 (30%) used z-score or t-test difference scores, and 9 (33%) used

classified as MCI at baseline but as intact at 1 week follow-up), the

a type of change score quantifier.

latter showed significant PEs, whereas the former did not.22 Thus, it
was the variability of PEs from initial to subsequent testing that served
as a potential more reliable diagnostic indicator. Finally, it should be

3.1

Theme 1: PE variability defines cases

noted that results on whether PEs could differentiate clinical groups
independently of baseline cognitive test performance were somewhat

Studies assigned to Theme 1 addressed the hypothesis that individuals

contradictory. For example, Zehnder et al. found that quantifying PEs

with MCI or AD had lower PEs than individuals with normal cogni-

did not add diagnostic accuracy to baseline cognitive test scores when

tive functioning.15,16,17,22,23,37 Most of these studies showed that

discriminating cognitively healthy from AD participants.37 In contrast,

8 of 12
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F I G U R E 2 Overview of different retest intervals across all included articles. (The Oltra-Cucarella et al. (2018) article was not included due to
large per subject retest interval range.)

Duff et al. showed that the predictive value of PEs was additive to

risk factors such as apolipoprotein E gene (APOE) ε4 alleles or a posi-

baseline cognitive performance after a 2-h retest interval.23

tive family history of dementia.14,32,33 In addition, attenuated PEs have
been found to be more common in groups with specific neuroimaging
markers that are indicative of dementia, such as lower cerebral blood

3.2
Theme 2: PE variability predicts future
cognitive decline

flow,27 brain hypometabolism,13 smaller hippocampal volumes,19 and
higher levels of amyloid.24,25,29 More specifically, Machulda et al.
showed that lower PEs were associated with lower hippocampal vol-

All Theme 2 articles addressed the hypothesis that lower PEs observed

ume and brain hypometabolism regardless of amyloidosis, suggesting

over time may be an important early indicator of future cogni-

that PEs were more closely related to neurodegeneration than amy-

tive decline. This was evidenced by associations between smaller

loid status.31 Studies linking PEs to neuropathology showed contrast-

or less robust PEs and (1) subsequent decline in cognitive test

ing findings. Galvin et al. reported the relationship between PE dif-

scores8,20,21,35 ; (2) risk of progression to AD9 ; (3) incidence of MCI

ferences and the presence of AD neuropathology among individuals

Most studies showed

who had died without a clinical diagnosis of dementia.26 Those with

that findings varied by cognitive domain, with abundant evidence that

AD pathology had lower PEs on episodic and semantic memory tests

lower PEs on episodic memory measures predicted future cognitive

than did those without AD pathology. In contrast, Wilson et al. did not

decline,9,18,21,32,34 whereas others found that the predictive value

identify a relationship between PEs over years and post-mortem neu-

or

dementia14,32,34 ;

and (4) terminal

decline.18

of PEs was largely consistent across different cognitive

domains.20

ropathological markers of AD in individuals without dementia.36

Furthermore, it should be noted that studies varied highly in terms
of retest intervals, which ranged from single-time retesting at the
same day,23 to multiple repeated assessments over several years32

4

DISCUSSION

(Figure 2).
The literature tends to characterize PEs as a nuisance in estimating
group-level characteristics such as normative decline over time in

3.3
Theme 3: PE variability associate with AD
risk factors and biomarkers

advanced age across different clinical and cognitive populations.2,38–40
In addition, in clinical neuropsychological evaluations, neuropsychologists are typically concerned with the question of whether individuals

The majority of articles we assigned to Theme 3 demonstrated that

show statistical evidence of change beyond that expected based on

lower PEs were associated with AD risk factors and biomarkers indica-

average PEs.3,41–46 In the current systematic review, we focused on

tive of neurodegeneration (Table 3). For example, several studies

a different question, namely whether individual-level PEs in older

showed that lower PEs were associated with greater presence of AD

adults could serve as a marker of clinical status, such that individuals
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TA B L E 3 Overview of studies with evidence for associations
between PEs and AD risk factors or biomarkers

an important early indicator of current diagnostic status and future
cognitive decline. In addition, lower PEs were associated with risk

Number of
articles
showing an
association

Number of
articles not
showing an
association

factors and markers indicative for dementia, such as APOE genotype

Presence of ≥ 1 APOE ε4 allele

3 [14, 27, 32]

3 [9, 24, 36]

performance and risk of dementia. Overall, 25 of those articles pro-

Higher amyloid uptake on amyloid
PET scans

4 [30-32, 34]

2 [33, 35]

vided support for one or more of our defined hypotheses (Figure 3).

Lower hippocampal volume

2 [29, 33]

1 [35]

is associated with (1) current cognitive performance or clinical status

Brain hypometabolism on FDG-PET

2 [13, 33]

0

(Theme 1) and/or (2) future cognitive decline and risk of progression to

Family history

1 [36]

1 [27]

AD dementia (Theme 2). Most of these studies were cross-sectional or

Cortical infarcts and hemorrhages

1 [34]

0

longitudinal comparisons between cognitively healthy older adults and

Lewy bodies

1 [34]

0

those with MCI or AD.8,15–17 However, one study suggested that char-

Braak stage

1 [34]

0

Finding

and biological markers of neurodegeneration.
Our review identified 27 articles evaluating evidence that characterized PEs in older adults can provide a marker for (future) cognitive

These studies supported the hypotheses that the magnitude of PEs

Abbreviations: FDG, fluorodeoxyglucose; PET, positron-emission tomography.

acterizing PEs in cognitively healthy individuals at baseline could aid
in the prediction of who would develop AD in the future.9 Lower PEs
were also found to be more common in groups with specific biological
markers (Theme 3), including brain metabolism, hippocampal volume,
and amyloid load.13,29,31 Together with Theme 2 findings, these results

who showed greater PEs would be at lower risk of future negative

suggest that the assessment of PEs, in combination with biomarkers,

cognitive/clinical outcomes than those who had lower PEs. Overall, we

could be used to detect preclinical AD. This would be of particular rel-

found consistent evidence from a modest-sized published literature

evance in the context of current AD research and clinical trials, which

that smaller, less robust PEs on repeated cognitive testing may be

are increasingly focusing on earlier, preclinical populations.11,47

FIGURE 3

Overview of the 25 articles providing evidence for one or more of the a priori defined hypotheses (Theme 1, 2, and/or 3)
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Although we identified accumulating evidence of the clinical value

were assigned to Category C. Therefore, we excluded several articles

of PEs in the study of AD, it should be noted that some findings remain

that focused on understanding mechanisms underlying PEs, for exam-

inconclusive. For instance, it is yet unclear whether PEs can predict

ple, by determining whether PEs can be attributed to repeated con-

future cognitive decline beyond baseline cognitive performance.37 In

tent rather than context effects,50 or by investigating different aspects

addition, some studies showed consistent results for PEs across mul-

of memory (eg, encoding vs. retrieval) as underlying mechanisms of

tiple cognitive domains,20 whereas other studies indicated that the

PEs.51 We note that those and other articles were not overlooked in

predictive value of PEs was

domain-specific.31

It is difficult to deter-

the review process, but rather fell outside the scope of the current

mine whether differences across studies reflected disparate assess-

review. On the other hand, novel, potentially eligible, Category C arti-

ment protocols or the selection of only statistically significant find-

cles may have been published while the current article was in prepara-

ings to present in publications. Findings regarding APOE ε4 status were

tion (eg52,53 ), but were not included as they were not available online

also contradictory; whereas three studies found that APOE ε4 carriers

before our final search date (January 2020). Although these two arti-

had lower PEs for memory,14 three other studies found no such asso-

cles were not included in this review, they provide further support for

ciation between APOE ε4 alleles and PEs.9,30,32 Unfortunately, it was

the hypothesis that the absence of PEs is a potential marker of cogni-

difficult to formally compare studies with contrasting findings, as the

tive decline.

studies reported varied highly with respect to retest intervals, diag-

This review provides an important stepping stone for future work

nostic groups, cognitive domains, biomarkers, and methods used to cal-

on PE as a useful marker in AD research. To our knowledge, this is the

culate and model PEs (see Table 2). Particularly the latter should be

first attempt to summarize the PE literature with a focus on PEs as a

taken into account when integrating the various findings. For example,

potential indicator of subsequent risk rather than as a source of bias

an empirical change score between the first- and second-time testing

in estimating group-level mean cognitive trajectories or as a confound-

captures PEs differently than, for example, a regression-based slope of

ing variable in determining whether an individual patient’s cognitive

performance across multiple years. The method that reflects PEs most

function has changed on a subsequent testing occasion. We performed

directly likely depends on multiple factors, such as the number and tim-

a comprehensive, systematic literature search followed by a thorough

ing of the repeated assessments.28,48 Although a full review of methods

review process benefiting from a multidisciplinary team with exper-

used to quantify PEs is beyond the scope of the current article, this is an

tise in cognitive aging, psychometrics, neuropsychology, medicine, and

important topic to address in future research.

library science. This study thus offers a novel valuable perspective on

Another important issue was the methodological complications of

the concept and implications of PEs in the study of cognitive aging

the included studies, such as, for example, small-sample sizes (eg,

and dementia. Most of the included articles supported the idea that

n < 5013,17,19,21,24,25 ), questionable definitions and classification crite-

lower PEs could reflect subtle learning deficits and thereby represent

ria used for diagnostic groups (eg, etiology of MCI unknown, no con-

an early clinical symptom of AD.

firmation of underlying neurodegeneration15–17 ), combining different

The idea that an absence of PEs could indicate (subtle) cognitive

clinical groups (eg, cognitively healthy and MCI subjects20 ), poten-

impairment, implies that researchers should consider characterizing

tial confounders affecting statistical analyses that were not accounted

PEs as a marker or risk factor of cognitive decline in studies of cog-

for,19 and varied definitions and methods to calculate PE49 . Due to

nitive aging and AD. For example, identifying individuals with lower

these overall differences as well as the heterogeneity of study design,

than expected PEs could potentially serve as a cost-effective strategy

participants, and measures, we were not able to conduct a formal meta-

to enrich enrollment in longitudinal studies, and predict who might be

analysis or include a funnel plot. However, it should be noted that the

at higher risk for developing AD. Furthermore, identifying high-risk

potential for publication bias, with respect to statistically significant

individuals may be an effective strategy to enroll high-risk individu-

results for the themes identified in this study, is likely to be high. That

als in randomized-controlled trials of disease-modifying therapeutics.

is, if we assume that a lack of PE is associated with cognitive decline,

To develop evidence-based recommendations for enrollment in clinical

and that on average the 27 studies were just adequately powered (ie,

trials, additional research is needed to determine the possible role of

had an 80% probability) to detect an association between lack of PE

lower PEs for estimating AD risk, and potentially in combination with

and cognitive decline, we would have only a 7% probability of observ-

other approaches such as AD biomarkers. We did not find any evalu-

ing ≥25 of 27 studies returning a significant effect. Moreover, the prob-

ations of PEs with respect to longitudinal imaging or fluid biomarker

ability of observing >25 of 27 studies with a positive effect would not

data, so it will be important to relate the magnitude of PEs to longi-

reach about 50% until the average power of the 27 studies exceeds

tudinal neuroimaging and biomarker data in future research. Further-

90%. We do not know the power of each of the 27 published studies,

more, methods for calculating PEs also warrant consideration in future

but an average of 90% seems implausible. Thus, it would be more plau-

work, as we found that those methods varied widely, which may have

sible that the number of studies performed is higher than 27, with all

accounted, in part, for contrasting findings across studies. Using more

of the other (non-published) studies not submitted because they had

sophisticated characterization of PEs across specific cognitive domains

“negative” findings. In this instance, the published literature may over-

and applying modern psychometric techniques to develop reliable esti-

represent statistically significant findings.

mates of learning and practice could improve identification of early

It should also be considered that, as our primary focus was on PEs as
a potential marker for cognitive decline, we included only articles that

stage AD. This, in turn, will help to clarify whether individuals with
lower PEs are at higher risk for conversion to AD.

JUTTEN ET AL .

In conclusion, we found accumulating evidence that a lack of PEs
may represent an early indicator of future cognitive decline and that
lower PEs are associated with specific AD biomarkers. The combination of PEs and these biomarkers may yield an optimal approach
to estimate AD risk. Future research could then focus on identifying high-risk cohorts from a combination of cognitive and clinical features, and lower than expected PEs. This cost-effective strategy may be able to enrich samples in clinical trials and provide a
valuable cognitive marker for subtle pharmacological or treatment
responses.
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